Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14–16, 2013
- 334 Downloads
With a record number of 760 international participants, 78 speakers and 264 abstracts, the 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) launched into its second decade. Recent breakthroughs in the clinic were reached for immune-modulatory antibodies (e.g., ipilimumab), dendritic cell (DC)-based vaccines (e.g., Provenge) and adoptive transfer of immune-receptor-engineered lymphocytes [e.g., CD19 chimeric antigen receptors (CARs)]. Despite the first success stories in the field, observed clinical responses are currently either mostly moderate or restricted to a fraction of patients or tumor entities. Consequently, the slogan for CIMT 2013 was ‘Advancing Targeted Therapies’ to the next level. Advances in the field to improve the success rates of immunotherapy were discussed within the community in sessions on cellular therapies, improving immunity, immunoguiding, combination therapy, tumor environment and tumor vaccination. The enthusiastically...
KeywordsCIMT 2013 Cancer immunotherapy Meeting report Targeted therapies
The authors would like to thank Dr. Stephen Reece (Mainz, Germany) for carefully proofreading the meeting report. Ute E. Burkhardt acknowledges support from the German Research Foundation (BU 3028/1-1). Selected sessions of the CIMT meeting were made possible due to research grants from the German Bundesministerium für Bildung and Forschung (BMBF grant: 031A018) and the Deutsche Forschungsgemeinschaft (DFG grant: GZ: HU 852/4-1; AOBJ: 602849). The CIMT-working group CIP receives support for educational activities by the Wallace Coulter Foundation (Florida, USA).
Conflict of interest
The authors declare that they have no conflict of interest. Cedrik M. Britten has been co-organizer of the meeting. Björn-Philipp Kloke has been co-organizer of the CIMT Endeavour workshop.